Interim no more: Ashley Magargee to fill Genentech CEO post; Pfizer, Moderna make commercial leadership adjustments
Ashley Magargee will become the CEO of Genentech on Jan. 1, two decades into her tenure at the South San Francisco biotech pioneer, which she joined prior to its $47 billion deal with now-parent Roche.
She’s held the interim post since Nov. 1, when Alexander Hardy left in a surprise move to take the same post at BioMarin. Magargee will report to the CEO of Roche Pharma, Teresa Graham, who herself worked up the corporate ladder of Genentech and Roche on a similar timetable and became the leader of its pharma business in March 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
